Reduction In Oral Mucositis With Avasopasem Manganese (GC4419) – Phase 3 Trial In Patients Receiving Chemoradiotherapy For Locally-Advanced, Non-Metastatic Head And Neck Cancer
Funded by
GENEVA
Research Start Date
Status
Active
The primary objective of this study is to assess the effect of GC4419 administered intravenously (IV) on the incidence and severity of severe oral mucositis (SOM) in subjects receiving post-operative or definitive therapy with single-agent cisplatin plus Intensity-Modulated Radiation Therapy (IMRT) for locally advanced, non-metastatic squamous cell carcinoma (SCC) of the oral cavity or oropharynx.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.